【摘要】 目的评价分析拜复乐治疗社区获得性肺炎的疗效。方法对68例社区获得性肺炎患者,予拜复乐“莫西沙星”(德国拜耳公司)400mg,静脉滴注,每日1次,疗程7d～10d。结果临床有效率为92.7%,细菌清除率为85.5%,药物不良反应发生率为4.4%。结论拜复乐安全有效,是目前治疗社区获得性肺炎的理想药物。更多还原

【Abstract】 Objective To evaluated the efficacy of moxifloxacin on community-acquired pneumonia. Methods 68 patients with community-acquired pneumonia were given moxifloxacin 400mg by intravenous infusion Qd. All patients had been treated for 7-14 days. Results The overall clinical effective rate was 92.7% and the bacterium clearance rate was 85.5%. The adverse effect incidence rate was 4.4%. Conclusion Moxifloxacin intravenous infusion is effective and safe for community-acquired pneumonia.更多还原